期刊
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
卷 17, 期 6, 页码 E211-E217出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1076029610397183
关键词
antiplatelet drugs; Multiplate; thrombocytopenia; in vitro platelet function
The Multiplate, a whole blood (WB) platelet function test, has shown promising results identifying patients on antiplatelet therapy at increased risk of rethrombosis. In the present study, the influence of low platelet count on platelet aggregation was analyzed and compared with aggregation results in an artificial matrix, platelet-rich plasma (PRP). Heparinized and citrated blood was diluted with autologous plasma to platelet concentrations 200 to 25 x 10(9)/L in WB samples (n = 10) and 200 to 100 x 10 9 /L in PRP samples (n = 7). The platelet aggregation was investigated by the ADP-, ASPI-, COL-, and TRAP-test. The WB responses decreased at platelet concentration of <= 100 x 10(9)/L (all P < .03), except for heparinTRAP (50 x 10(9)/L, P = .008) and citrate-ASPI (150 x 10(9)/L, P = .03). In general, WB samples demonstrated higher aggregation than PRP samples at platelet concentrations 200 to 100 x 10(9)/L (P < .05). In conclusion, platelet concentration of < 150 x 10(9)/L may influence Multiplate which should be considered in clinical settings. Furthermore, the findings emphasize the importance of evaluating haemostasis in its natural matrix, WB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据